Pfizer misses quarterly sales estimates as COVID treatment revenue falls
April 29 (Reuters) - U.S. drugmaker Pfizer PFE.N reported first-quarter revenue below Wall Street estimates on Tuesday, hurt by a decline in sales of its COVID antiviral treatment, Paxlovid.
It reported total revenue of $13.70 billion for the first quarter, compared with analysts' expectations of $13.91 billion, according to LSEG data.
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Recommended Articles
Featured Tools
Top News
Micron Stock Forecast: Can the AI Memory Super-Cycle Drive MU to $3,000 by 2030?

Tesla Opens Up Over 2%, Shares Return to $400, Here Is What Investors Need to Note

Gold Price Forecast: U.S.-Iran Tensions Ease, Nonfarm Payrolls Looming, What’s Next for Gold?

SpaceX IPO Approaches: Musk Dissolves xAI into SpaceX and Subleases 300MW Compute to Anthropic; Can the $2 Trillion Valuation Hold?

WTI and Brent Futures Both Fall Below $100 Mark, Have Oil Prices and Energy Sector Peaked?

Tradingkey








